Pre-Exposure Prophylaxis

The CDC on Wednesday recommended that all sexually active adults and adolescent patients be informed about HIV PrEP.

Only around a quarter of Hispanic/Latino people receiving a CDC-funded HIV test were aware of PrEP, and an even smaller proportion of those eligible for the HIV prevention medication were referred to a PrEP provider, a study found.

For some time now, we have been discussing COVID-19 as two epidemics. One is the tragic and unnecessary epidemic among those unwilling to be vaccinated who are pushing our fragile health care system to the limit, unnecessarily spreading the infections throughout the community, including to the most vulnerable. The other is one of breakthrough infections in those who have done what they can to protect themselves by being partially or fully vaccinated.

In a small study, researchers detected gastrointestinal pathogens in 45% of men who have sex with men taking HIV PrEP, according to findings published in Open Forum Infectious Diseases.

A retrospective analysis showed increasing disparities in HIV PrEP uptake between early and late adopting states between 2014 and 2018, researchers reported.

On-site access to PrEP during a clinical trial reduced HIV incidence by around 50%, according to a study of South African women published in The Lancet HIV.

The annual incidence of HIV in the United States declined 73% from a peak of 130,400 infections in 1984 and 1985 to 34,800 infections in 2019, according to estimates published today in MMWR.

The CDC released a draft of revised clinical practice guidelines for HIV PrEP and took feedback from clinicians via two webinars held May 24 and 25.

ViiV Healthcare said Tuesday that it has initiated a rolling submission of a new drug application for long-acting injectable cabotegravir for HIV PrEP.

Marginalization and stigma are directly related to poor physical and mental health outcomes, according to a speaker at the ACP Internal Medicine Meeting, held virtually.